RETATRUTIDE

Retatrutide is a triple agonist peptide targeting GIP, GLP-1 and glucagon receptors simultaneously. Unlike dual-agonist compounds, Retatrutide also activates the glucagon receptor, giving it a unique pharmacological profile for metabolic research. Studies have focused on energy homeostasis, body composition and metabolic pathway modulation. Retatrutide is currently one of the most sought-after research peptides in the UK. Supplied as lyophilised powder, third-party tested, lab certificate published on this page.

Intended Use: Strictly for in-vitro laboratory research. Not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics. This product has not been evaluated by the MHRA or FDA. Buyer assumes full responsibility for safe handling and regulatory compliance.